Myocardial Strain Imaging

Policy # 00672
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers myocardial strain imaging in individuals who have exposure to medications or radiation that could result in cardiotoxicity to be investigational.*

Based on review of available data, the Company considers myocardial strain imaging in all other situations to be investigational.*

Background/Overview
The term strain indicates dimensional or deformational change under force. When used in echocardiography, the term ‘strain’ is used to describe the magnitude of shortening, thickening, and lengthening of the myocardium through the cardiac cycle. The most frequent measure of myocardial strain is the deformation of the left ventricle in the long axis, termed global longitudinal strain. During systole, ventricular myocardial fibers shorten with movement from the base to the apex. Global longitudinal strain is used as a measure of global left ventricle function and provides a quantitative myocardial deformation analysis of each left ventricle segment. Myocardial strain imaging is intended to detect subclinical changes in left ventricle function in patients with a preserved left ventricle ejection fraction, allowing for early detection of systolic dysfunction. Since strain imaging can identify left ventricle dysfunction earlier than standard methods, this raises the possibility of heart failure prophylaxis and primary prevention before the patient develops symptoms and irreversible myocardial dysfunction. Potential applications of speckle-tracking echocardiography are coronary artery disease, ischemic cardiomyopathy, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathies, stress cardiomyopathy, and chemotherapy-related cardiotoxicity.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Myocardial Strain Imaging

Myocardial strain can be measured by cardiac magnetic resonance imaging (MRI), tissue Doppler imaging or by speckle-tracking echocardiography. Tissue Doppler strain imaging has been in use since the 1990s but has limitations that include angle dependency and significant noise. In 2016, Smiseth et al reported that the most widely used method of measuring myocardial strain at the present time is speckle-tracking echocardiography. In speckle-tracking echocardiography, natural acoustic markers generated by the interaction between the ultrasound beam and myocardial fibers form interference patterns (speckles). These markers are stable, and speckle-tracking echocardiography analyzes the spatial dislocation (tracking) of each point (speckle) on routine 2-dimensional sonograms. Echocardiograms are processed using specific acoustic-tracking software on dedicated workstations, with offline semiautomated analysis of myocardial strain. The 2-dimensional displacement is identified by a search with image processing algorithms for similar patterns across 2 frames. When tracked frame-to-frame, the spatiotemporal displacement of the speckles provides information about myocardial deformation across the cardiac cycle. Global longitudinal strain provides a quantitative analysis of each left ventricle segment, which is expressed as a percentage. In addition to global longitudinal strain, speckle-tracking echocardiography allows evaluation of left ventricle rotational and torsional dynamics.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
A number of image analysis systems have been cleared for marketing by the U.S. FDA through the 510(k) process. Examples of these are shown in Table 1. For example, the Echolnsight software system (Epsilon Imaging) "enables the production and visualization of 2-dimensional tissue motion measurements (including tissue velocities, strains, strain rates) and cardiac structural measurement information derived from tracking speckle in tissue regions visualized in any B mode (including harmonic) imagery loops as captured by most commercial ultrasound systems" (K110447). The FDA determined that this device was substantially equivalent to existing devices (eg.syngo US Workplace, Siemens, K091286) for analysis of ultrasound imaging of the human heart.

Table 1. Examples of Software That Have Received FDA Clearance

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Manufacturer</th>
<th>510(k) Number</th>
<th>FDA Product Code</th>
<th>Clearance Date</th>
</tr>
</thead>
</table>

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Myocardial Strain Imaging

Policy # 00672
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021

<table>
<thead>
<tr>
<th>Myostrain</th>
<th>Myocardial Solutions</th>
<th>K182756</th>
<th>LNH</th>
<th>02/14/2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vivid</td>
<td>GE</td>
<td>K181685</td>
<td>IYN</td>
<td>10/25/2018</td>
</tr>
<tr>
<td>Aplio</td>
<td>Toshiba</td>
<td>IYN</td>
<td>01/11/2018</td>
<td></td>
</tr>
<tr>
<td>2D CARDIAC PERFORMANCE ANALYSIS</td>
<td>Tomtec</td>
<td>K120135</td>
<td>LLZ</td>
<td>04/13/2012</td>
</tr>
<tr>
<td>Echolnsight</td>
<td>Epsilon Imaging</td>
<td>K110447</td>
<td>LLZ</td>
<td>05/27/2011</td>
</tr>
<tr>
<td>Q-lab</td>
<td>Phillips</td>
<td>K023877</td>
<td>LLZ</td>
<td>12/23/2002</td>
</tr>
</tbody>
</table>

FDA: Food and Drug Administration.

**Rationale/Source**

Myocardial strain refers to the deformation (shortening, lengthening, or thickening) of the myocardium through the cardiac cycle. Myocardial strain can be measured by tissue Doppler imaging or, more recently, speckle-tracking echocardiography. Speckle-tracking echocardiography uses imaging software to assess the movement of specific markers in the myocardium that are detected in standard echocardiograms. It is proposed that a reduction in myocardial strain may indicate sub-clinical impairment of the heart and can be used to inform treatment before development of symptoms and irreversible myocardial dysfunction.

For individuals who have exposure to medications or radiation that could result in cardiotoxicity who receive myocardial strain imaging, the evidence includes a systematic review of observational studies. Relevant outcomes include symptoms, morbid events, quality of life, treatment-related mortality, and treatment-related morbidity. A systematic review of 13 studies with 384 patients treated for cancer suggests that myocardial strain imaging with tissue Doppler imaging or speckle-tracking echocardiography may be able to identify changes in myocardial deformation that precede changes in left ventricle ejection fraction. Although myocardial strain imaging may detect sub-clinical myocardial changes, the value of these changes in predicting clinical outcomes or guiding therapy is uncertain. No studies were identified that compared the diagnostic accuracy of myocardial...
Strain imaging to left ventricle ejection fraction. A study that will compare clinical outcomes when therapy is guided by myocardial strain imaging or left ventricle ejection fraction is in progress and will provide direct evidence on the clinical utility of myocardial strain imaging. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Cardiology et al
In 2019, the American College of Cardiology, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons published appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease (Table 2).

Using a modified Delphi approach, the panel rated indications as “appropriate”, “may be appropriate”, and “not appropriate”. The specific studies that formed the basis of the American College of Cardiology guidelines are not cited, however, they note that they used American College of Cardiology/American Heart Association clinical practice guidelines whenever possible.

Of 81 indications considered for strain rate imaging, the panel rated only 4 as “appropriate” (Table 2). Three of the 4 concerned evaluation (initial or follow-up) in patients prior to and following exposure to potentially cardiotoxic agents. The other indication was follow-up testing to clarify initial diagnostic testing for patients with suspected hypertrophic cardiomyopathy. The guidelines
did not separate out imaging with speckle tracking and tissue Doppler and did not make recommendations related to the comparative effectiveness of these imaging modalities.

The panel rated 14 other indications “may be appropriate” (Table 2). According to the panel, interventions in this category should be performed depending on individual clinical patient circumstances and patient and provider preferences, including shared decision making.

Table 2. Summary of ACC Appropriate Use Criteria for Myocardial Strain Imaging

<table>
<thead>
<tr>
<th>Clinical Scenario and Indication</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial evaluation in an asymptomatic patient:</td>
<td></td>
</tr>
<tr>
<td>- Initial evaluation prior to exposure to medications/radiation that could result in cardiotoxicity/heart failure</td>
<td>Appropriate</td>
</tr>
<tr>
<td>- Initial cardiac evaluation of a known systemic, congenital, or acquired disease that could be associated with structural heart disease</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>- Screening evaluation for structure and function in first-degree relatives of a patient with an inherited cardiomyopathy</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>- Preparticipation assessment of an asymptomatic athlete with 1 or more of the following: abnormal examination, abnormal ECG, or definite (or high suspicion for) family history of inheritable heart disease</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>Initial evaluation of a patient with clinical signs and/or symptoms of heart disease:</td>
<td></td>
</tr>
<tr>
<td>- Initial evaluation when symptoms or signs suggest heart disease</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>- Arrhythmias or conduction disorders: Newly diagnosed LBBB; Nonsustained VT</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>- Palpitations/presyncope/syncope: Clinical symptoms or signs consistent with a cardiac diagnosis known to cause presyncope/syncope (including but not limited to hypertrophic cardiomyopathy and heart failure)</td>
<td>May be appropriate</td>
</tr>
</tbody>
</table>
Clinical Scenario and Indication | Rating
--- | ---
- Respiratory failure/exertional shortness of breath: Exertional shortness of breath/dyspnea or hypoxemia of uncertain etiology | May be appropriate
- HF/cardiomyopathy: Initial evaluation of known or suspected HF (systolic or diastolic) based on symptoms, signs, or abnormal test results to assess systolic or diastolic function and to assess for possible etiology (CAD, valvular disease); Suspected inherited or acquired cardiomyopathy (eg, restrictive, infiltrative, dilated, hypertrophic) | May be appropriate
- Device therapy: Known implanted pacing/ICD/CRT device with symptoms possibly due to suboptimal device settings | May be appropriate
- Cardiac transplantation: Monitoring for rejection or coronary arteriopathy in a cardiac transplant recipient | May be appropriate
- Other: Suspected pericardial diseases | May be appropriate

Sequential or follow-up testing to clarify initial diagnostic testing:

- Evaluation of suspected hypertrophic cardiomyopathy | Appropriate
- Re-evaluation (1 y) in a patient previously or currently undergoing therapy with potentially cardiotoxic agents | Appropriate
- Periodic reevaluation in a patient undergoing therapy with cardiotoxic agents and worsening symptoms | Appropriate
- Pulmonary hypertension in the absence of severe valvular disease | May be appropriate
- Comprehensive further evaluation of undefined cardiomyopathy | May be appropriate
- Evaluation of suspected cardiac amyloidosis | May be appropriate

Sequential or follow-up testing: new or worsening symptoms or to guide therapy
Myocardial Strain Imaging

Policy # 00672
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021

<table>
<thead>
<tr>
<th>Clinical Scenario and Indication</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Re-evaluation of known structural heart disease with change in clinical status or cardiac examination or to guide therapy</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>Re-evaluation of known cardiomyopathy with a change in clinical status or cardiac examination or to guide therapy</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac examination without a clear precipitating change in medication or diet</td>
<td>May be appropriate</td>
</tr>
<tr>
<td>Re-evaluation for CRT device optimization in a patient with worsening HF</td>
<td>May be appropriate</td>
</tr>
</tbody>
</table>

ACC: American College of Cardiology; CAD: coronary artery disease; CRT: cardiac resynchronization therapy; ECG: electrocardiogram; HF: heart failure; ICD: implantable cardioverter-defibrillator; LBBB: left bundle branch block; VT: ventricular tachycardia.

Source: Adapted from Doherty et al (2019).

**American Society of Clinical Oncology**
In 2017, the American Society of Clinical Oncology noted that measurement of strain has been demonstrated to have some diagnostic and prognostic use in patients with cancer receiving cardiotoxic therapies but that there have been no studies demonstrating that early intervention based on changes in strain alone can result in changes in risk and improved outcomes. The American Society of Clinical Oncology also notes that screening for asymptomatic cardiac dysfunction using advanced imaging could lead to added distress in cancer survivors.

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Medicare National Coverage**
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Myocardial Strain Imaging

Policy # 00672
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 3.

The Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes (SUCCOUR) is a randomized controlled trial (RCT) that will evaluate clinical outcomes for patients who are monitored by myocardial strain imaging or conventional imaging. Patients with an abnormal test result will receive improved blood pressure and glucose control. Protective therapy with angiotensin-converting enzyme inhibitors and beta-blockers will be titrated to target dose. This will be the first trial to assess clinical outcomes based on myocardial strain imaging compared to conventional imaging (limited to evaluation of ejection fraction and valve disease). The SUCCOUR trial will provide evidence to inform guidelines regarding the place of global longitudinal strain for surveillance for cardiotoxicity.

Table 3. Summary of Key Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td>ACTRN12614000341628 Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.</td>
<td>320</td>
<td>Aug 2021</td>
</tr>
<tr>
<td></td>
<td>NCT03825224 Evaluation of MyoStrain in Clinical Practice</td>
<td>100</td>
<td>Feb 2020</td>
</tr>
<tr>
<td></td>
<td>NCT02605512 Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients (BACCARAT)</td>
<td>120</td>
<td>Sep 2020</td>
</tr>
<tr>
<td></td>
<td>NCT02286908 Global Strain and Mechanical Dispersion May Predict Death and Ventricular Arrhythmias Better Than Ejection Fraction</td>
<td>3100</td>
<td>Dec 2021</td>
</tr>
</tbody>
</table>
## Myocardial Strain Imaging

**Policy # 00672**  
**Original Effective Date:** 08/01/2019  
**Current Effective Date:** 09/13/2021

### Study Breakdown

<table>
<thead>
<tr>
<th>Study</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03297346</td>
<td>Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY-HEART)</td>
<td>250</td>
<td>May 2021</td>
</tr>
<tr>
<td>NCT04547465</td>
<td>2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy with Cardiovascular Risk Factors</td>
<td>300</td>
<td>Jun 2023</td>
</tr>
<tr>
<td></td>
<td><em>Unpublished</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03543228a</td>
<td>MyoStrain CMR for the Detection of Cardiotoxicity (Prefect)</td>
<td>50</td>
<td>Jun 2019</td>
</tr>
</tbody>
</table>

ACTRN: Australia New Zealand Clinical Trials Registration Number; NCT: national clinical trial.  
a Denotes industry-sponsored or cosponsored trial.

### References

Myocardial Strain Imaging

Policy # 00672
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021


Policy History
Original Effective Date: 08/01/2019
Current Effective Date: 09/13/2021
05/02/2019 Medical Policy Committee review
05/15/2019 Medical Policy Implementation Committee approval. New policy.
06/04/2020 Medical Policy Committee review
06/10/2020 Medical Policy Implementation Committee approval. Investigational policy statement added to address cardiotoxicity.
08/05/2021 Medical Policy Committee review
08/11/2021 Medical Policy Implementation Committee approval. No change to coverage.
Next Scheduled Review Date: 08/2022
Myocardial Strain Imaging

Policy #  00672
Original Effective Date:  08/01/2019
Current Effective Date:  09/13/2021

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>93356</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C9762, C9763</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Myocardial Strain Imaging

Policy #  00672  
Original Effective Date:  08/01/2019  
Current Effective Date:  09/13/2021

standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.